Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > WOW...did Paul REALLY say this??? Exciting if he DID !!!

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Sep 28, 2022 10:38pm

181 Views

Post# 34993907

RE:RE:RE:RE:RE:WOW...did Paul REALLY say this??? Exciting if he DID !!!

I completely agree! I think this statement means more at this stage of the clinical trial, than it would have in pre-clinical or even during the Ph.1a, but still leaves plenty of outs if it turns out not to be true. This is a remarkable statement considering.

longterm56 wrote: This sounds like something that would be said in pre-clinical research, like 3 years ago! I don't know how to interpret it recognizing the person who said it knows how the 3 months of phase 1b is going. Totally stumped.

Biobob wrote: This is met with lot of sceptism for now.... they cried Wolfe before.... but it's encouraging until we know more... October 13 maybe....